$EVO

Evotec SE (EVO) announced that Dr. Cord Dohrmann, its Chief Scientific Officer, will resign on Sept. 30, 2026, after 16 years. The company is seeking a successor. Separately, JPMorgan Chase filed a routine German major-holdings notice for Evotec SE on Sept. 24, 2026, without disclosing stake details.

Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) announced that Dr. Cord Dohrmann will step down as Chief Scientific Officer on September 30, 2026. The decision was mutual, and the company is searching for a successor. Dr. Dohrmann served for 16 years, contributing to scientific advancements. Evotec's CEO praised his role in strengthening the company's scientific capabilities. The company's future growth is expected to rely on the science infrastructure built by Dr. Dohrmann.

Evotec SE (EVO) began a Phase 1 trial for JST-018, a monoclonal antibody cocktail targeting orthopoxviruses, under a U.S. Department of War program. Developed by its subsidiary Just - Evotec Biologics, the therapy aims to protect against threats like smallpox and mpox. The stock traded at $1.82 on Tuesday, down 2.15%, and was at $1.83 in pre-market trading.

Evotec SE (EVO) and Plectonic Biotech have entered a research collaboration to explore a new immunotherapy approach for solid tumors. The partnership combines Evotec's BiTco platform, which enhances T cell activation, with Plectonic's LOGIBODY® technology, designed for precise tumor recognition. The goal is to improve the precision and potency of T-cell-engaging therapies. Preclinical data will be generated to evaluate the potential of this combined approach.

Evotec SE (EVO) reported Q2 2026 revenue of €143.5m, down from €171.2m, and adjusted EBITDA of -€20.8m. H1 revenue fell to €300.1m from €371.2m, with adjusted EBITDA -€42.7m. It reaffirmed FY2026 guidance: revenue €570-€610m and adjusted EBITDA -€70 to -€105m, citing partnership phasing and slower new ramp-ups.

Evotec SE (EVO) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 For further information, please contact : Dr. Sarah Fakih, EVP Head of Global Communications and Investor Relations, sarah.fakih@evotec.com, M. +49.(0)151 70 688 784, www.evotec.com INTERIM STATEMENT 6M 2026 HIGHLIGHTS 4 D&PD NET SALES 1 EXCLUDING STRATEGIC PARTNERSH

Evotec (NASDAQ: EVO) reaffirmed its FY2026 sales guidance of $667.470 million to $714.310 million, unchanged from prior outlook and near the consensus estimate of $673.750 million. The company also announced an R&D collaboration with Odyssey Therapeutics (NASDAQ: ODTX) to discover small-molecule candidates for autoimmune and inflammatory diseases, with milestone payments and no disclosed upfront terms.

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

Evotec SE (NASDAQ: EVO) said it entered an R&D collaboration with Odyssey Therapeutics (NASDAQ: ODTX) to use Evotec’s AI-enabled discovery platform and screening capabilities to discover and validate small-molecule drug candidates for autoimmune and inflammatory diseases. Evotec will deliver validated hit series across multiple targets and may receive milestone payments; no financial terms were disclosed.

Evolution AB (publ) said it bought 207,007 of its own shares on 3 Aug 2026, pushing its treasury shareholding above the 5% notification threshold. The company now holds 9,985,643 own shares, or 5.01% of 199,226,613 shares and votes. The buyback is part of a program for up to 19,922,661 shares and EUR 2 billion announced 18 May 2026.